Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression

Blood

Volumn 103, Issue 1, 2004, Pages 50-57

  Socié, Gérard ^a,b   Mary, Jean Yves ^a   Lemann, Marc ^a   Daneshpouy, Marjan ^a   Guardiola, Philippe ^a   Meignin, Véronique ^a   Ades, Lionel ^a   Esperou, Hélène ^a   Ribaud, Patricia ^a   Devergie, Agnès ^a   Gluckman, Eliane ^a   Ameisen, Jean Claude ^a   Janin, Anne ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE DISEASE; ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CHILD; CHRONIC DISEASE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DUODENUM BIOPSY; ENDOSCOPIC BIOPSY; FEMALE; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE HISTOCHEMISTRY; STOMACH BIOPSY; TRANSPLANT RELATED MORTALITY; TRANSPLANTATION;

EID: 9144251094     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0909     Document Type: Article

References (54)

1. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553-558.
2. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964-2968.
3. Deeg HJ. Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction. Int J Hematol. 2001;74:26-32.
4. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754-2759.
5. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the fas pathway in acute graft-versus-host disease. J Immunol. 1996;157:5387-5393.
6. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood. 1998;91:4051-4055.
7. Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood. 1999;93:2738-2747.
8. Iwasaki T, Hamano T, Saheki K, et al. Graft-versus-host-disease-associated donor cell engraftment in an F-I hybrid model is dependent upon the Fas pathway. Immunology. 2000;99:94-100.
9. Ferrara J. A major minor for GvHD. Blood. 2002;100:4255.
10. Choi EY, Christianson GJ, Yoshimura Y, et al. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood. 2002;100:4259-4265.
11. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol. 2001;115:630-641.
12. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99:2726-2733.
13. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GvHD grading. Bone Marrow Transplant. 1995;15:825-828.
14. Gavrieli Y, Sherman Y, Ben Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
15. Sale GE, Shulman HM, McDonald GB, Thomas ED. Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy. Am J Surg Pathol. 1979;3:291-299.
16. Epstein RJ, McDonald GB, Sale GE, Shulman HM, Thomas ED. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology. 1980;78:764-771.
17. Washington K, Bentley RC, Green A, et al. Gastric graft-versus-host disease: a blinded histologic study. Am J Surg Pathol. 1997;21:1037-1046.
18. Cox DR. Regression models and life-tables (with discussions), series B. J Roy Stat Soc. 1972;34:184-192.
19. Daneshpouy M, Socie G, Lemann M, et al. Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood. 2002;99:3033-3040.
20. Brown GR, Thiele DL. T-cell activation and differentiation are regulated by TNF during murine DBA/2→B6D2F1 intestinal graft-versus-host disease. J Clin Immunol. 2000;20:379-388.
21. Cheng J, Turksen K, Yu QC, et al. Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev. 1992;6:1444-1456.
22. Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999;104:459-467.
23. Hill GR, Teshima T, Rebel VI, et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol. 2000;164:656-663.
24. Speiser DE, Bachmann MF, Frick TW, et al. TNF receptor p55 controls early acute graft-versus-host disease. J Immunol. 1997;158:5185-5190.
25. Dickinson AM, Sviland L, Jackson G, et al. Monoclonal anti-TNF-alpha suppresses graft vs host disease reactions in an in vitro human skin model. Cytokine., 1994;6:141-146.
26. Facon T, Jouet JP, Noel-Walter MP, et al. Involvement of TNF-alpha secreting macrophages in lethal forms of human graft-versus-host disease. Bone Marrow Transplant. 1997;20:511-515.
27. Holler E, Kolb HJ, Mittermuller J, et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood. 1995;86:890-899.
28. Huang XJ, Wan J, Lu DP. Serum TNF alpha levels in patients with acute graft-versus-host disease after bone marrow transplantation. Leukemia. 2001;15:1089-1091.
29. Remberger M, Ringden O, Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant. 1995;15:99-104.
30. Robinet E, Pico JL, Ibrahim A, et al. Lack of correlation between serum levels and receptor expression of TNF alpha and graft versus host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1991;7(suppl 2):148. Abstract 148.
31. Sakata N, Yasui M, Okamura T et al. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/s TNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant. 2001;27:1153-1161.
32. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987;166:1280-1289.
33. Cooke KR, Hill GR, Gerbitz A, et al. Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation. J Immunol. 2000;165:6612-6619.
34. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graff-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581-1589.
35. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882-1891.
36. Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999;104:459-467.
37. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 1998;102:115-123.
38. Hill GR, Cooke KR, Brinson YS, Bungard D, Ferrara JL. Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1999;67:1478-1480.
39. Hill GR, Teshima T, Rebel VI, et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol. 2000;164:656-663.
40. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213.
41. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995;155:585-593.
42. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med. 2001;194:1433-1440.
43. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood. 1992;79:3362-3368.
44. Holler E, Koib H J, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011-1016.
45. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood. 1998;91:4051-4055.
46. van den Brink MR, Moore E, Horndasch KJ, et al. Fas-deficient Ipr mice are more susceptible to graft-versus-host disease. J Immunol. 2000;164:469-480.
47. van den Brink MR, Moore E, Horndasch KJ, et al. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease. Transplantation. 2000;70:184-191.
48. Janin A, Deschaumes C, Daneshpouy M, et al. CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood. 2002;99:2940-2947.
49. Facon T, Janin A, Noel MP, Jouet JP. Involvement of macrophages in lethal forms of graft-versushost disease [letter] Lancet. 1995;345:392.
50. Serody JS, Burkett SE, Panoskaltsismortari A, et al. T-lymphocyte production of macrophage inflammatory protein-1 alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood. 2000;96:2973-2980.
51. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest. 1999;104:49-57.
52. Ferrara JL, Teshima T. Reply to "Is alloantigen expression by host epithelium required for acute graft-versus-host disease?" [letter]. Nat Med. 2003;9:151.
53. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575-581.
54. Martin P, Nash R, Sanders J, et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant. 1998;21:273-279.